News Archive

Commercializing Technologies for Societal Impact

The governments of the United States of America (through the Department of State) and India (through the Department of Science & Technology) have established the United States – India Science & Technology Endowment Fund (USISTEF) for the promotion of joint activities that would lead to innovation and technopreneurship through the application of science and technology. The Endowment Fund activities are implemented and administered through the bi-national Indo-US Science and Technology Forum (IUSSTF).

The fund aims to select and financially support promising joint U.S.-India entrepreneurial initiatives that address the theme of “Commercializing Technologies for Societal Impact” through a competitive grant program.

OpGen announced today that it has signed a supply agreement with Thermo Fisher Scientific to combine its Acuitas Rapid Test for Pathogen ID with Thermo Fisher’s real-time PCR solutions.

The biotech industry remains poised for growth, EY said in its annual industry report released today, despite continuing pressure from payers to contain drug prices and an investor pullback from capital markets that helped deflate profits and slow down revenue growth for public companies last year.

“Beyond Borders: Staying the Course” observed that while biotechs will continue to pursue the prices they seek for new drugs by citing their value—either in patient outcomes or lower costs—so too will payers seek to contain those prices.

A provocative study published earlier this month in the journal Science and Public Policy contends that Europe lacks the cutting-edge science long seen in the U.S., and increasingly published in Asia: “Europe lags far behind the USA in the production of important, highly cited research,” co-authors Alonso Rodríguez-Navarro, Ph.D., of Universidad Politécnica de Madrid, and Francis Narin, Ph.D., founder of CHI Research (now The Patent Board).

Technology talent often found in California’s tech mecca Silicon Valley is starting to spread to other parts of the U.S., thanks to the rising cost of living in the Bay Area and government tax breaks for companies that move to another state. And because of that, Baltimore is starting to see growth in the industry.

“Processors are overdesigned for most applications,” says University of Illinois electrical and computer engineering professor Rakesh Kumar. It’s a well-known and necessary truth: In order to have programmability and flexibility, there’s simply going to be more stuff on a processor than any one application will use. That’s especially true of the type of ultralow power microcontrollers that drive the newest embedded computing platforms such as wearables and Internet of Things sensors. These are often running one fairly simple application and nothing else (not even an operating system), meaning that a large fraction of the circuits on a chip never, ever see a single bit of data.

The “birthplace of biotechnology” is to receive $10 million for a pioneering precision medicine programme.

It was announced this week that the California Initiative to Advance Precision Medicine (CIAPM) has been awarded the money from the local government’s budget, a decision welcomed by the California Life Sciences Association (CLSA).

When Ripley Ballou — Rip to his friends — started to feel sick at a party in 1987, he thought it was because of his friend’s home-brewed beer.

Ballou was taking a break from his work on developing a malaria vaccine at the Walter Reed Army Institute of Research in Silver Spring, Maryland, which he was doing in collaboration with the pharmaceutical giant GlaxoSmithKline (GSK). Back then, researchers could be a principal investigator as well as volunteer in their own projects.

Typically when someone gets #Cancer, it is not the initial tumor that kills them. At some point, the tumor spreads to other parts of the body, such as the brain, the liver, or other parts to the point where it becomes untreatable. What if a therapy could be developed that could slow or even stop this process? A post-doctorate fellow at #Johns Hopkins may well have discovered such a therapy, according to the Baltimore Sun.